Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.
Enlace externo para Anaconda BioMed
Eivissa 56
SANT Quirze del Vallés, Barcelona 08192, ES
Anaconda BioMed ha compartido esto
“The IDE approval marks an exciting milestone in our company’s mission to deliver new, safe and effective solutions that can meaningfully improve the treatment of stroke." Anaconda BioMed has announced that it has received conditional IDE approval from the FDA to begin the ATHENA study of its ANA Funnel Catheter. Read more: https://lnkd.in/eX8HkjfA #MedTech #Catheters #Regulation
Anaconda BioMed ha compartido esto
Anaconda Biomed are developing next-generation thrombectomy systems. They have announced a conditional IDE approval from the U.S. FDA to begin the ATHENA study of its ANA Funnel Catheter. This prospective, randomized, multi-center study will assess the safety and effectiveness of the ANA Funnel Catheter in combination with a stent retriever for mechanical #thrombectomy. “The IDE approval marks an exciting milestone in our company’s mission to deliver new, safe, and effective solutions that can meaningfully improve the treatment of stroke,” said Anaconda Biomed CEO Francois Salmon. Dr.Adnan Siddiqui, MD, PhD, coordinating investigator of the ATHENA study, added, “The neurointerventional community is eager to assess this innovative technology, which is designed to enhance the efficiency of mechanical thrombectomy. Even a small difference in revascularization success after one pass can have a profound impact on the clinical outcomes of people with ischemic stroke.” Studies indicate that flow arrest during mechanical thrombectomy can improve revascularization rates and clinical outcomes. However, this approach has been underutilized due to current device limitations. Anaconda Biomed’s ANA Funnel Catheter is uniquely designed to facilitate flow arrest during clot retrieval. Upon IRB approval, the ATHENA study will be conducted at up to 40 U.S. and international centers, enrolling patients with acute #ischemic stroke treated within 24 hours of symptom onset. The study will report acute reperfusion success after a single thrombectomy pass and procedural safety between study arms. Congratulations to Francois, Ofir Arad, David Harari, Hendrik Lambert and the wider Anaconda BioMed team! #neurointerventional #idestudy #neurovascular #stroke
We have very exciting news: ''We have received conditional IDE approval from the U.S. Food and Drug Administration to begin the ATHENA study of its ANA Funnel Catheter'' Press Release: https://lnkd.in/duYyKEjc Thank you very much 🐍
Remembering with a lot of emotional hangover the last team building we did last June, "CONDAYAK" 🌊. A very special moment was the celebration of our colleagues who have completed 5 years in Anaconda! 😍 As always we enjoyed two wonderful days together as a team 😜. We are lucky to be part of an organisation where people are at the centre of everything, and we work to create connections outside the workplace 💚. #CONDAYAK #teambulding #newexperiences
Our CEO, Francois Salmon, was at the MedTech Strategist in Dublin to demonstrate Anaconda Biomed's dedication to finding a safe and efficient way to perform a mechanical thrombectomy. A big thank you to everyone involved and to all those who support our project 🐍 Innogest Capital Ysios Capital Omega Funds Asabys Partners #MedTechStrategist #MedTechInnovation
Now presenting at #InnovationDublin24 is Anaconda BioMed with CEO Francois Salmon Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI The ANA5 system from Anaconda Biomed (Sant Quirze -Barcelona- Spain) is intended to be inserted and navigated to the neurovascular anatomy. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction. The device is indicated for restoring blood flow in patients experiencing an acute ischemic stroke due to large vessel occlusion. Anaconda Biomed aims to increase penetration of mechanical thrombectomy for stroke by optimizing its device to achieve the benefits of “The First Pass Effect.
Yesterday was a very special day, it was Anaconda's 9th anniversary!!! 🐍 🎂 Thank you to all the people who make this project possible, you are a fundamental part of our work.🧡 Innogest Capital, Ysios Capital, Omega Funds, Asabys Partners Lunch: L'obrador catering Delicious!
🍾 MedTech Strategist is honored to welcome Anaconda BioMed alongside CEO Francois Salmon as a Presenting Company at the 10th Annual Innovation Summit Dublin 2024. 🧠 Presenting in the Stroke and Mechanical Thrombectomie Therapeutic Categories, The ANA5 system from Anaconda Biomed (Sant Quirze -Barcelona- Spain) is intended to be inserted and navigated to the neurovascular anatomy. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction. The device is indicated for restoring blood flow in patients experiencing an acute ischemic stroke due to large vessel occlusion. 🥂 Welcome to #InnovationDublin24, Francois and Anaconda Biomed! 🤝 Celebrate 10 years of Innovation Summit in Dublin, Ireland April 16-18, 2024. Request to register now: https://bit.ly/48M8npY #medtech #medicaldevices #medtechindustry #medtechinnovation #stroke #strokeawareness #strokecare
Última ronda
Serie B22.165.012,00 US$